Acasti Pharma Incの将来のP / E
Acasti Pharma Incの将来のP / Eは何ですか。
Acasti Pharma Incの将来のP / Eは-3.61です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるAcasti Pharma Inc
Acasti Pharma Incは何をしますか。
acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
Acasti Pharma Incと類似の将来のp / e
- Vir Biotechnology Incの将来のP / Eは-3.70です。
- Rare Element Resourcesの将来のP / Eは-3.68です。
- comScoreの将来のP / Eは-3.68です。
- Cellectis SAの将来のP / Eは-3.65です。
- InflaRx N.Vの将来のP / Eは-3.63です。
- Medicinova Incの将来のP / Eは-3.61です。
- Acasti Pharma Incの将来のP / Eは-3.61です。
- comScoreの将来のP / Eは-3.61です。
- comScoreの将来のP / Eは-3.61です。
- Standard BioTools Incの将来のP / Eは-3.60です。
- Arbutus Biopharma Corpの将来のP / Eは-3.60です。
- comScoreの将来のP / Eは-3.59です。
- comScoreの将来のP / Eは-3.59です。